Media about us

27 November 2017

Contract pharmaceutical manufacturing sites in Russia are very relevant

GMP News

A round table on Contract Manufacturing of Pharmaceutical Products was held on November 22, 2017, at Pharmtech & Ingredients 2017, the 19th international exhibition of equipment, raw materials and technologies for pharmaceutical manufacturing. The event moderator was Alexander Kuzin, the General Director at NovaMedica. 

23 October 2017

Contract R&D market is developing in Russia

GMP News

NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.

23 October 2017

Russian pharmaceutical map has a new point of convergence

GMP News

An interesting international pharmaceutical project has started in Russia. This project is a result of a convergence of interests of Rusnano, Russian state investment corporation, Domain Associates, an American venture capital foundation, and Pfizer, an American pharmaceutical corporation.  

20 October 2017

NovaMedica receives a license for production site at its R&D center

GMP News

NovaMedica received a license from the FBI SID & GP for a pilot production site at its R&D center. This was announced by Alexander Kuzin, the General Director of the company.

08 September 2017

New 30-minute STI test allows just one clinic trip

Helen Clark / Gears of Biz

A new speedy test will mean that for the first time ever patients with common sexually-transmitted infections will be able to get their diagnosis and treatment in one clinical visit. The test works by placing a swab or a small amount of urine into a test cartridge, which is then inserted into the diagnostic machine, which has been designed by innovation firm Atlas Genetics Ltd.

07 September 2017

Roche to up Russian Gazyva supply through local fill/finish deal

Dan Stanton / BioPharma Reporter.com

Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa. The policy has driven most multinationals to sign contracts with domestic drugmakers and invest in local joint ventures. Pfizer broke ground on a facility with NovaMedica in Kaluga in May, GSK formed a JV with Binnopharm in 2011, while AstraZeneca , Novartis and Novo Nordisk have all invested in Russian production facilities.

17 August 2017

Prostate Cancer: Epic Sciences AR-V7 Test

OncLive

Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.

29 June 2017

Syndax Locks In To Tumor Escape

Seeking Alpha

Syndax (NASDAQ:SNDX) is a $315 million market cap company focused on developing a pipeline of innovative combination therapies for cancer. The company's lead product is Entinostat, which was granted Breakthrough Therapy Designation by FDA for its Phase 2b clinical trial in advanced hormone receptor positive (Estrogen Receptor positive, ER+) breast cancer. The impact of Breakthrough Therapy Designation on biotechnology stocks has been previously described here by Strong Bio and is worth a read. The company has a host of impressive partnerships for its clinical trials, including Merck (NYSE:MRK) for a combinatory non-small cell lung cancer (NSCLC) and melanoma therapy, Genentech/Roche (OTCQX:RHHBY) for triple-negative breast cancer (TNBC), and Pfizer (NYSE:PFE) and Merck in Germany for ovarian cancer.

16 June 2017

LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

LA BioMed

The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

15 June 2017

OD reports practice’s success with corneal inlay

Jeffrey M. Augustine, OD / Healio

The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.